682 Trial in progress: phase 1 trial of TSC-100 and TSC-101, engineered T-cell therapies targeting minor histocompatibility antigens to eliminate residual disease after hematopoiet... by Yun Wang, Ran Reshef, Gavin MacBeath, Jim Murray, Debora Barton, Erica Buonomo, Shrikanta Chattopadhyay, Monzr Al Malki, Alla Keyzner, Hyung C Suh, Aasiya Matin, Nina Abelowitz